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Type 1 diabetes is characterized by an immune-mediated depletion of b-cells that
results in lifelong dependence on exogenous insulin. While both type 1 and type 2
diabetes result in hyperglycemia, the pathophysiology and etiology of the diseases
are distinct and require us to consider each type of diabetes independently. As such,
this position statement summarizes available data specific to the comprehensive
care of individuals with type 1 diabetes. The goal is to enhance our ability to
recognize and manage type 1 diabetes, to prevent its associated complications,
and to eventually cure and prevent this disease.
INCIDENCE AND PREVALENCE OF TYPE 1 DIABETES
The exact number of individuals with type 1 diabetes around the world is not
known, but in the U.S., there are estimated to be up to 3 million (1). Although it
has long been called “juvenile diabetes” due to the more frequent and relatively
straightforward diagnosis in children, the majority of individuals with type 1 di-
abetes are adults.
Most children are referred and treated in tertiary centers, where clinical data are
more readily captured. The SEARCH for Diabetes in Youth study estimated that, in
2009, 18,436 U.S. youth were newly diagnosed with type 1 diabetes (12,945 non-
Hispanic white, 3,098 Hispanic, 2,070 non-Hispanic black, 276 Asian-Pacific Islander,
and 47 American Indian) (2). Worldwide, ;78,000 youth are diagnosed with type 1
diabetes annually. Incidence varies tremendously among countries: East Asians
and American Indians have the lowest incidence rates (0.1–8 per 100,000/year) as
comparedwith the Finnishwho have the highest rates (.64.2 per 100,000/year) (3). In
the U.S., the number of youth with type 1 diabetes was estimated to be 166,984 (4).
The precise incidence of new-onset type 1 diabetes in those over 20 years of age is
unknown. This may be due to the prolonged phase of onset and the subtleties in
distinguishing the different types of diabetes. In one European study of adults aged
30–70 years, ;9% tested positive for GAD antibodies (GADA) within 5 years of a
diabetes diagnosis, consistent with other studies (5).
Adults with type 1 diabetes often receive care in primary care settings rather than
with an endocrinologist. Unlike the consolidated care seen in pediatric diabetes man-
agement, the lack of consolidated care in adults makes incidence and prevalence rates
difficult to characterize, and therefore they are often underestimated. The number of
adults living with type 1 diabetes is increasing due to two factors: 1) the rising number
of new-onset cases of type 1 diabetes in adults, including those diagnosed with latent
autoimmune diabetes in adults (LADA), and 2) individuals with childhood-onset di-
abetes are living longer (6,7).
CLASSIFICATION AND DIAGNOSIS
Type 1 diabetes has traditionally been diagnosed based on clinical catabolic symp-
toms suggestive of insulin deficiency: polyuria, polydipsia, weight loss, and marked
hyperglycemia that is nonresponsive to oral agents. It is classified as an autoimmune
disease with progressive b-cell destruction, resulting in a physiological dependence
on exogenous insulin. Recent studies have broadened our understanding of the
disease, but have made diagnosis more complex.
There is tremendous variability in the initial presentation of type 1 diabetes in
both youth and adults. Children often present acutely, with severe symptoms of polyuria,
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polydipsia, and ketonemia. However, in
adults, type 1 diabetes presents with a
more gradual onset, with a clinical pre-
sentation thatmay initially appear consis-
tent with type 2 diabetes. Distinguishing
between type 1 and type 2 diabetes
presents diagnostic challenges. Tradition-
ally, progressive b-cell destruction has
been the hallmark of type 1 diabetes,
but residual C-peptide (a surrogatemarker
for insulin secretion)maybedetectedover
40 years after initial diagnosis, regardless
of whether the initial diagnosis was made
in childhood or in adulthood (8).
Clinical Clues
Much of the diagnosis will depend on
clinical clues, but the rising incidence
of overweight/obesity has also con-
founded the diagnosis of type 1 diabetes.
A lean individual presenting with clinical
symptoms without a first-degree relative
with diabetes (but often with a history of
distant relatives with type 1 diabetes or
other autoimmune disease) is generally
suggestive of type 1 diabetes. An over-
weight individual (of any age) with meta-
bolic syndrome anda strong family history
of type 2 diabetes may be assessed only
for the development of type 2 diabetes,
even though type 1 diabetes is on the
differential diagnosis. Obesity does not
preclude that autoimmunity and hyper-
glycemia will occur even amid the rela-
tively higher levels of endogenous insulin
secretion observed in obesity. In young
patients aged 10–17 years with pheno-
typic type 2 diabetes, 10% have evidence
of islet autoimmunity suggesting that
type 1 diabetes was the likely diagnosis
(9). Thus, although leaner individuals are
more likely to be diagnosed as having
type 1 diabetes, the potential for type 1
diabetes exists in those who phenotypi-
cally appear to have type 2 diabetes. If
hyperglycemia persists after treatment
with noninsulin agents, which is unusual
in the treatment of newly diagnosed type
2 diabetes, then type 1 diabetes should
be considered.
Pancreatic Autoantibodies
Pancreatic autoantibodies are charac-
teristic of type 1 diabetes. Highly sensi-
tive laboratory measurements capture
;98% of individuals with autoantibod-
ies at diagnosis (10). Unfortunately,
most commercial laboratories do not
have reliably sensitive or specific assays
that measure all five autoantibodies:
GADA, islet cell antibodies (ICA), insulin
autoantibodies (IAA), protein tyro-
sine phosphatase antibodies (ICA512
or IA2A), and zinc transporter protein
(ZnT8). Thus, it may be inappropriate
to report a patient as autoantibody neg-
ative. Another cause of “false-negative”
autoantibodies is testing far out from
diagnosis as antibody titers diminish
over time (Fig. 1). It appears that there
is an increased incidence of type 1 di-
abetes in ethnic populations where au-
toantibody markers may be of variable
utility, such as in Asians where autoanti-
bodies are often negative (11–15).
Family History
Type 1 diabetes has a genetic predilection
and, in some cases, can be predicted in
family members. The overall prevalence
of type 1 diabetes in the U.S. is ;0.3%,
but if a first-degree relative has diabetes,
the empiric risk of being affected is ;5%
(17,18), representing a 15-fold increase
among family members. Studies evaluat-
ing children at risk for developing type 1
diabetes have shown that the presence of
more than two autoantibodies was asso-
ciated with a nearly 70% risk for disease
development within 10 years and 84%
within 15 years (19). Evaluating at-risk in-
dividuals in the clinical setting is not yet
recommended due to limited clinical in-
terventions; however, ongoing research
studies are identifying at-risk individuals
through genetic testing in both the lower-
risk general population and in the higher-




c The American Diabetes Association’s
(ADA’s) diagnostic criteria for type 1
and type 2 diabetes are the same
(Table 1). (A)
c Consider measurement of pancreatic
autoantibodies to confirm the diag-
nosis of type 1 diabetes. (B)
Identification of At-Risk Relatives
c Inform type 1 diabetic patients of the
opportunity to have their relatives
tested for type 1 diabetes risk in the




All patients with type 1 diabetes
need age-appropriate care, with an
understanding of their specific needs
and limitations. Infants and toddlers
are approached quite differently from
Figure 1—The percentage of antibody-positive subjects is affected by the duration of type 1 diabetes for GADA (A) and IA2A (B). Given an increase in the
scatter (due to lower numbers of subjects), the x-axis is truncated at a duration of 30 years. Reproduced with permission from Tridgell et al. (16).
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adolescents; the needs of young adults
may vary from middle-aged or older
adults. Regardless of age, the patient’s
needs are the same: an individualized
care plan with ongoing education and
support, ongoing assessment for acute
and chronic complications, and access
to medical providers with type 1 diabe-
tes expertise. Just as patients change,
the therapeutic approach should change
and should be evaluated at each visit and
modified as needed.
Type 1 diabetes care must be an iter-
ative process, adapted as the needs of
the individual evolve. Clinical assess-
ments for type 1 diabetes in children and
adults should incorporate age-appropriate
and complication-focused evaluations,
based on the likelihood that an abnormal-
ity will be present. For example, a young
adult with low cardiovascular disease
(CVD) risk and no complications may
need more of an assessment of lifestyle
adjustment as opposed to an older adult
with longer duration of the disease who
may needmore evaluation of vascular and
neurological issues.
Transition of Care From Pediatric to
Adult Providers
As youth transition into emerging adult-
hood, the supportive infrastructure of-
ten abruptly disappears and glycemic
control tends to deteriorate. The ADA
recognizes that this is a challenging
time and recommends a strong, practi-
cal transition plan to anticipate the up-
coming changes. A successful transition
plan should be initiated early (e.g., early
teenage years) and include ongoing di-
alogue between the family and youth.
The discussion should include finances,
insurance, obtainment of supplies, iden-
tification of an adult care provider (ide-
ally with communication between the
two providers), psychosocial issues (e.g.,
depression), and other issues identified
by the family/youth. Health care pro-
viders, family, and youth should agree to
an achievable diabetes management plan
and provide resources for unanticipated
issues. We refer the reader to the ADA’s
position statement on diabetes care for
emerging adults (20).
Table 2 provides the childhood devel-
opmental phases and needs. Tables 3, 4,
and 5 provide detailed elements of the
initial and follow-up evaluation in indi-
viduals with type 1 diabetes.
Assessing the history of acute compli-
cations (e.g., severe hypoglycemia/
hyperglycemia and diabetic ketoacido-
sis [DKA]) is important. Providers should
provide continuing education for the
patient/family to prevent ongoing re-
currence. For example, it is important
to review exercise management to re-
duce hypoglycemia risk and discuss sick-
day management to reduce DKA risk.
Risk factor (e.g., cardiovascular) evalu-
ation for prevention and screening for
early evidence of micro- and macrovascu-
lar complications for early intervention
should be implemented starting in ado-
lescence and continue through adult-
hood. For children, risk factors should be
assessed shortly after diagnosis based on
family history and initial screening labo-
ratory test results. Providers should man-
age risk factors, considering age-specific
goals and targets (e.g., blood pressure,
lipid, depression, and BMI assessment
and management). The frequency of on-
going screening for complications should
be based on age and disease duration.
Coexistent Autoimmunity
Celiac Disease
Celiac disease is an immune-mediated
disorder that occurs with increased
frequency in patientswith type1 diabetes
(1–16% of individuals compared with
0.3–1% in the general population)
(21,22). Symptoms of celiac disease in-
clude diarrhea,weight loss or poorweight
gain, abdominal pain, bloating, chronic
fatigue, malnutrition due to malabsorp-
tion, and unexplained hypoglycemia or
erratic blood glucose levels. Screening
for celiac disease with serum levels of tis-
sue transglutaminase or antiendomysial
antibodies should be considered soon
after the diagnosis of diabetes and/or if
symptoms develop. Individuals who test
positive should be referred to a gastroen-
terologist for possible small-bowel biopsy
to confirm the diagnosis, although this is
not necessary in all cases. Symptomatic
children with strongly positive antibodies
and supportive genetic or HLA testing
may not require a biopsy, but asymptom-
atic at-risk children should have a biopsy
(23). In symptomatic individualswith type
1 diabetes and confirmed celiac disease, a
gluten-free diet reduces symptoms and
decreases rates of hypoglycemia (24).
Thyroid Disease
About one-quarter of children with type
1 diabetes have thyroid autoantibodies
(thyroid peroxidase antibodies or antithy-
roglobulin antibodies) at the time of di-
agnosis (25,26). The presence of thyroid
autoantibodies is predictive of thyroid
dysfunction, generally hypothyroidism
and less commonly hyperthyroidism (27).
Thyroid dysfunction is more common in
adults with type 1 diabetes, although the
exact prevalence is unknown. Women
are more commonly affected than men.
Subclinical hypothyroidism, hyperthy-
roidism, or coexistent Addison disease
(adrenal insufficiency) may also deterio-
rate metabolic control with increased risk
of symptomatic hypoglycemia (28) and
may reduce linear growth in children (29).
Additional Considerations for
Pediatrics
All children require some level of adult
supervision in managing their diabe-
tes. Assessments of pediatric patients
should address issues specific to infants/
preschoolers, school-aged children, ado-
lescents, and emerging adults (Table 2).
Health care providers should do a thor-
ough assessment of the developmental
needs of the youth (and caregiver), fo-
cusing on physical and emotional devel-
opment, family issues, and psychosocial
needs. The diabetes treatment plan
Table 1—Criteria for the diagnosis of diabetes
A1C $6.5%. The test should be performed in a laboratory using a method that is NGSP
certified and standardized to the DCCT assay.*
OR
FPG $126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.*
OR
Two-hour plasma glucose $200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test.
The test should be performed as described by the World Health Organization, using
a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.*
OR
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma
glucose $200 mg/dL (11.1 mmol/L).
*In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.
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should be individualized and tailored
to the needs of individual patients
and their families. Efforts to achieve
target blood glucose and A1C levels
should be balanced with preservation
of quality of life and protect against
excessive hypoglycemia.
Height and weight should be measured
at each visit and tracked via appropriate
height and weight growth charts. An age-
adjusted BMI can be calculated starting at
age 2 years. These tools can be found for
children and teens at http://apps.nccd
.cdc.gov/dnpabmi. Blood pressure mea-
surements shouldbedetermined correctly,
using the appropriate size cuff and
with the child seated and relaxed. Hyper-
tension should be confirmed on at least 3
separate days. Normal blood pressure
levels for age, sex, and height and appro-
priate methods for determinations are
available online at www.nhlbi.nih.gov/
health/prof/heart/hbp/hbp_ped.pdf.
Chronic Complications in Children
Retinopathy, nephropathy, and neurop-
athy rarely have been reported in pre-
pubertal children and children with
diabetes duration of only 1–2 years;
however, they may occur after the onset
of puberty or after 5–10 years of diabetes
(30). As screening recommendations are
based on recent evidence, these periodi-
cally change. Therefore, we refer the
reader to the ADA Standards of Care for
the current screening recommendations
for children. It is recommended that those
with expertise in diabetes management
should conduct the assessments. For ex-
ample, ophthalmologic exams should be
performed by those skilled in diabetic ret-
inopathy management and experienced
in counseling pediatric patients and pa-
rents on the importance of early preven-
tion/intervention. Another example,
Table 2—Major developmental issues and their effect on diabetes in children and adolescents
Developmental stages (ages) Normal developmental tasks
Type 1 diabetes
management priorities
Family issues in type 1
diabetes management
Infancy (0–12 months) Developing a trusting relationship




Avoiding extreme fluctuations in
blood glucose levels
Sharing the burden of care to avoid
parent burnout
Toddler (13–26 months) Developing a sense of mastery
and autonomy
Preventing hypoglycemia Establishing a schedule
Avoiding extreme fluctuations in
blood glucose levels due to
irregular food intake
Managing the picky eater
Limit-setting and coping with
toddler’s lack of cooperation
with regimen




Developing initiative in activities
and confidence in self
Preventing hypoglycemia Reassuring child that diabetes is no
one’s faultCoping with unpredictable
appetite and activity Educating other caregivers about
diabetes managementPositively reinforcing cooperation
with regimen




Developing skills in athletic,
cognitive, artistic, and
social areas
Making diabetes regimen flexible
to allow for participation in
school or peer activities
Maintaining parental involvement
in insulin and blood glucose
management tasks while
allowing for independent self-
care for special occasions
Consolidating self-esteem with
respect to the peer group
Child learning short- and long-term
benefits of optimal control




Managing body changes Increasing insulin requirements
during puberty
Renegotiating parent and
teenager’s roles in diabetes
management to be acceptable
to both
Developing a strong sense
of self-identity Diabetes management and blood
glucose control becoming
more difficult Learning coping skills to enhance
ability to self-manageWeight and body image concerns
Preventing and intervening in
diabetes-related family conflict
Monitoring for signs of depression,




Establishing a sense of identity
after high school (decisions
about location, social issues,
work, and education)
Starting an ongoing discussion of
transition to a new diabetes
team (discussion may begin
in earlier adolescent years)




Learning coping skills to enhance
ability to self-manage
Preventing and intervening with
diabetes-related family conflict
Monitoring for signs of depression,
eating disorders, and risky
behaviors
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nephrologists with experience with dia-
betic nephropathy would be aware that
intermittent elevations in urinary albu-
min excretion are common in pediatric
patients, particularly in association with
exercise.
Additional Considerations for Adults
Adults with type 1 diabetes now span a
very large age spectrumdfrom 18 to
100 years of age and beyond. Unlike
the well-characterized developmental
stages of children, the life stages tra-
versed through adulthood are often
less well documented and underappre-
ciated. However, an understanding of
each individual’s circumstances is vital.
This is true for aging in general, but par-
ticularly true for those with significant
comorbidities due to long-standing
type 1 diabetes. Thus, it is important to
assess the clinical needs of the patient,
setting specific goals and expectations
that may differ significantly between a
healthy 26-year-old and a frail 84-year-
old with CVD and retinopathy.
Recommendations
See 2014 ADA Standards of Medical Care
for detailed screening information for
CVD, nephropathy, retinopathy, neurop-
athy, and foot care.
c Access to health care should include
clinicians with expertise in type 1
diabetes management, including
(but not limited to) an endocrinolo-
gist (or other health care provider
with expertise in type 1 diabetes
management), a registered dietitian,
a diabetes educator, a mental health
professional, an exercise specialist/
physiologist, and specialists required
to treat diabetes complications. (E)
c Routine follow-up (generally quar-
terly) should include review of
self-monitoring of blood glucose
(SMBG), continuous glucose monitor-
ing (CGM) and pump data (if applica-
ble), A1C measurement, evidence for
acute and/or chronic complications of
diabetes (particularly episodes of DKA
and mild and/or severe hypoglycemia),
measurement of blood pressure
and weight (and height in children),
foot exam, inspection of injection/
insertion sites, and discussion of psycho-
social and educational needs (Tables 4
and 5). (E)
c Providers should routinely document
the patient’s age and disease duration.
When clinically indicated, laboratory
measures such as lipids, renal function
measurements, and antibodies for as-
sociated autoimmune disease (thyroid
or celiac disease) should be docu-
mented. (E)
c Parent/guardian involvement in care
is required throughout childhood,
with a gradual shift in responsibility
of care from the parent/guardian to
the youth. (E)
c Health care for adults should be fo-
cused on the needs of the individual
throughout the various stages of their
life, with age-appropriate evaluation
and treatment. (E)
c Evaluation and treatment of CVD risk
should be individualized. (E)
c Immunizations should be given as
recommended by the Centers for Dis-
ease Control and Prevention (CDC) for
children/adults in general and people
with diabetes specifically. (C)
c Consider screening for celiac disease
by measuring IgA antitissue transgluta-
minase or antiendomysial antibodies,
with documentation of normal total
serum IgA levels, soon after the diag-
nosis of diabetes and/or if symptoms
develop. Refer the patient to a gastro-
enterologist if the test is positive. (E)
c Consider screening for thyroid peroxi-
dase and thyroglobulin antibodies soon
after diagnosis. (E)
c Screen for thyroid dysfunction by mea-
suring thyroid-stimulating hormone
(TSH) concentrations soon after type 1
diabetes diagnosis (and after stable
metabolic control). If normal, consider
rechecking every 1–2 years or more fre-
quently if the patient develops unusual
glycemic variation or symptoms of thy-
roid dysfunction or thyromegaly. (E)
c Assess for the presence of additional
autoimmune conditions at diagnosis
and if symptoms develop. (E)
c Ongoing nutrition and diabetes self-
management education (DSME) and
support (DSMS) are needed to ad-
dress changes in food preferences,
access to food, daily schedules, activ-
ity patterns, and potential barriers to
Table 3—Medical history
Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic laboratory finding)
Eating patterns, physical activity habits, nutritional status, and weight history
Whether or not patient wears medical alert identification
Diabetes education history; health literacy assessment
Review of previous insulin treatment regimens and response to therapy (A1C records),
treatment preferences, and prior difficulty with therapies
Current treatment of diabetes, including medications and medication adherence, meal plan,
physical activity patterns, and readiness for behavior change
Use of insulin, insulin pumps, carbohydrate ratios, and corrections; knowledge of sick-day
rules; ketone testing; pump troubleshooting (if applicable)
Results of glucose monitoring, including SMBG and CGM and patient’s use of data
DKA frequency, severity, and cause
Hypoglycemic episodes
Hypoglycemia unawareness
Any severe hypoglycemia: frequency and cause
Whether or not patient has glucagon available and someone to administer it
History of diabetes-related complications
Microvascular: retinopathy, nephropathy, and neuropathy (sensory, including history of
foot lesions; autonomic, including sexual dysfunction and gastroparesis)
Macrovascular: coronary heart disease, cerebrovascular disease, and peripheral artery
disease
Other: dental disease
Psychosocial issues, including current or past history of depression, anxiety, eating disorders,
and others; assess support systems and need for assistance
History of pregnancy and any diabetes-related complications; desire for future pregnancies
Contraception (if a woman is of childbearing age)
Smoking
Alcohol use, abuse, and impact on blood glucose levels
Illicit drug use
Driving
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Table 4—Children and adolescents*
Clinical evaluation Initial Annual Quarterly follow-up
Height X X X
Weight X X† X†
BMI percentile X X X
Blood pressure X X X
General physical exam X X
Thyroid exam X X X
Injection/infusion sites X (if already on insulin) X X
Comprehensive foot exam‡ If needed, based on age Beginning with older teens
with diabetes since childhood
Visual foot exam X If needed, based on
high-risk characteristics
Retinal exam by eye care specialist X§ In some cases, may be done
every 2 years (see ADA
Standards of Care)
Depression screen X X X
Hypoglycemia assessment X X X
Diabetes self-management skills X X X
Physical activity assessment X X X
Assess clinically relevant issues
(e.g., alcohol, drug, and tobacco
use; use of contraception; driving)
X As needed for teens As needed for teens
Nutritional knowledge X X As needed
Query for evidence of other
autoimmune disease
X As needed As needed
Immunizations as recommended by CDC X X As needed
Laboratory assessments Initial Annual Follow-up




Lipid panel|| Once glycemia is stable X As needed based on
treatment
TSH X X As needed based on
treatmentFrequency of testing varies
based on clinical symptoms,
presence of antibodies,




X Repeat as clinically indicated
Frequency of testing is unknown;
test if symptoms are present
or for periodic screening
Celiac antibody panel X Repeat as clinically indicated
Frequency of testing is unknown;
test if symptoms are present
or for periodic screening





May be needed in new-onset
patients to establish diagnosis
C-peptide levels X
Occasionally needed to establish
type 1 diabetes in a patient





*Assumes a patient has a health care provider to manage the nondiabetes-related health assessments and to perform annual evaluations. †Patient
may opt out of measurement if psychologically distressing. ‡Foot inspection should be done at each visit and self-exams taught if high-risk
characteristics are present. Comprehensive foot exam includes inspection, palpation of dorsalis pedis and posterior tibial pulses, presence or
absence of patellar and Achilles reflexes, and determination of proprioception, vibration, and monofilament sensation. §Within 5 years after
diagnosis. ||If triglycerides are elevated in a nonfasting specimen, measure a direct LDL cholesterol level.
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Table 5—Adults*
Clinical evaluation Initial Annual Follow-up
Height X
Weight X X† X†
BMI X X
Blood pressure X X X
General physical exam X
Thyroid exam X If indicated
Injection/infusion sites X X X
Comprehensive foot exam‡ X X
Visual foot exam As neededdat each
visit, if high-risk foot
Retinal exam by eye care
specialist§
Starting 5 years after diagnosis;
earlier if visual symptoms and/or
true date of diagnosis is unknown
In some individuals, screening
may be done every 2 years (see
ADA Standards of Medical Care)
Depression screen X X
Hypoglycemia assessment X X X
Diabetes self-management skills X X X
Physical activity assessment X X X
Assess clinically relevant issues
(e.g., alcohol, drug, and tobacco
use; use of contraception; driving)
X As needed As needed
Nutritional knowledge X X As needed
Query for evidence of other
autoimmune disease
X As needed based on
clinical scenario




X X As needed
Laboratory assessments Initial Annual Follow-up




Fasting lipid panel|| X X As needed based on
treatment
TSH X X As needed based on
treatmentFrequency of testing varies based
on clinical symptoms, presence
of antibodies, or if on treatment
Antithyroid antibodies X
Frequency of testing is unknown;
test if symptoms are present
or for periodic screening
Celiac antibody panel X
Frequency of testing is unknown;
test if symptoms are present
or for periodic screening
Urine albumin-to-creatinine ratio X X
GADA X
May be needed in new-onset
patients to establish diagnosis
C-peptide levels X
Occasionally needed to establish
type 1 diabetes in a patient on insulin
or to verify type 1 diabetes for
insurance purposesdalways
measure a simultaneous blood
glucose level
*Assumes a patient has a health care provider to manage the nondiabetes-related health assessments and to perform annual evaluations. †Patient
may opt out of measurement if psychologically distressing. ‡Foot inspection should be done at each visit and self-exams taught if high-risk
characteristics are present. Comprehensive foot exam includes inspection, palpation of dorsalis pedis and posterior tibial pulses, determination
of presence or absence of patellar and Achilles reflexes, and determination of proprioception, vibration, and monofilament sensation. §In some
instances, the test may not need to be done yearly. ||If a patient is unable to undertake a fasting test due to hypoglycemia, measure a direct LDL
cholesterol level.
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self-care, including the risk of an eat-
ing disorder. (E)
c Assess psychosocial status annually
and more often as needed; treat
and/or refer to a mental health pro-
fessional as indicated. (E)
DSME AND DSMS
DSME and DSMS are the ongoing pro-
cesses of facilitating the knowledge,
skill, and ability necessary for diabetes
self-care. These processes incorporate
the needs, goals, and life experiences
of the person with diabetes. The overall
objectives of DSME and DSMS are to
support informed decision making,
self-care behaviors, problem solving,
and active collaboration with the
health care team to improve clinical
outcomes, health status, and quality
of life in a cost-effective manner (31).
Because changes in both treatment
and life circumstances occur across
the life span, DSME and DSMS must be
a continuous process adapted through-
out the life of the person with type 1
diabetes so that self-management can
be sustained.
No matter how sound the medical
regimen, it can only be as successful as
the ability of the individual and/or fam-
ily to implement it. Family involvement
remains an important component of
optimal diabetes management through-
out childhood and adolescence. Health
care providers who care for children and
adolescents must, therefore, be capable
of evaluating the educational, behav-
ioral, emotional, and psychosocial fac-
tors that impact implementation of a
treatment plan and must assist the in-
dividual and family to overcome bar-
riers or redefine goals as appropriate
(Table 6). Diabetes education should
occur at diagnosis and upon transition
to adult diabetes care and should be an
ongoing process. The information needs
to be individualized and continually
adapted to the patient’s needs.
Recommendations
c Individuals with type 1 diabetes and
parents/caregivers (for individuals
aged ,19 years) should receive cul-
turally sensitive and developmentally
appropriate individualized DSME
and DSMS according to national
standards for DSME and DSMS when
their diabetes is diagnosed and rou-
tinely thereafter. (B)
Table 6—DSME content based on life stages
Infancy (birth–18 months)
Period of trust versus mistrust
Providing warmth and comfort measures after invasive procedures is important
Feeding and sleeping or nap routines
Vigilance for hypoglycemia
Play age (3–5 years)
Reassurance that body is intact, use of Band-Aids and kisses after procedures
Identification of hypoglycemic signs and symptoms (temper tantrums and nightmares are common)
Include child in choosing injection and finger-prick sites
Positive reinforcement for cooperation
Begin process for teaching child awareness of hypoglycemia
School age (6–12 years)
Integrate child into educational experience
Determine skill level
Identify self-care skills
Determine roles and responsibilities
Communication with peers and school staffdwho and when to tell about diabetes
Adolescence (12–18 years)
Begin transition care planning
Personal meaning of diabetes
Determine roles and responsibilities in care
Social situations and dating
Who or when to tell about diabetes
Driving
Sex and preconception counseling
Alcohol and drugs
College and career planning
Young adults
Personal meaning of diabetes
Roles and responsibilities in care
Social situations and dating
Who or when to tell about diabetes
Genetic risks, conception, and preconception
Travel
Choosing or pursuing a career
Workplace rights
Health or life insurance
Involving friends and significant others in diabetes care
Safety
Creating a support network
Establishing or maintaining independence
Middle-aged adults
Personal meaning of diabetes
Roles and responsibilities in care
Involving spouse or significant other in care
Sexual functioning




Health or life insurance
Talking with children or other family members about diabetes




Personal meaning of diabetes
Roles and responsibilities in care
Maintaining independence
Obtaining assistance with diabetes care tasks
Involving spouse or significant other in care
Travel
Talking with adult children or other family members about diabetes
Safety
Assessing for declines in ability to perform self-care/activities of daily living
Caring for diabetes along with other chronic illnesses or comorbidities
Obtaining health care when living in multiple locations
Community resources
Care of type 1 diabetes in long-term or other care facilities
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Additional Considerations for
Pediatrics
c Education should be provided to ap-
propriate school personnel as a signif-
icant portion of a child’s day is spent
in school. (E)
c The developing teenager must be edu-
cated about the transition to adult
health care, beginning in early to mid-
adolescence, with increasing efforts to
establish self-reliance in diabetes care
beginning at least 1 year prior to the
transition. Even after the transition to
adult care is made, support and rein-
forcement are recommended. (E)
Additional Considerations for Adults
c Adult learning theory can be used to
tailor DSME and DSMS to the age, life
stage, culture, literacy/numeracy,
knowledge, experience, and cognitive




Assessment and appropriate manage-
ment of psychosocial issues are important
throughout the life span of individuals
with type 1 diabetes. In pediatrics, health
care providers should assess the individ-
ual child and the child’s family for their
ability to function and behave appropri-
ately regarding safe and responsible dia-
betes care. For adults, the individual is
the focus of care. However, family involve-
ment should be strongly encouraged
when appropriate.
Depression screening and discussion
about psychosocial issues are important
components of the diabetes visit. Special
attention should be paid to diabetes-
related distress, fear of hypoglycemia
(and hyperglycemia), eating disorders, in-
sulin omission, subclinical depression,
and clinical depression. These factors
are significantly associated with poor di-
abetes self-management, a lower quality
of life, and higher rates of diabetes com-
plications. As individuals age, health care
providers should evaluate issues related
to self-care capacity, mobility, and
autonomy. Such factors are to be
promptly addressed, as they make the
management of type 1 diabetes ever
more problematic.
Recommendations
c Make age-appropriate screenings for
psychosocial issues a component of
most diabetes visits. Any concerns
should be pursued through treatment




c Ensure that there is developmentally
appropriate parent/family involve-
ment in the management of the
child’s/adolescent’s diabetes care
tasks, avoiding a premature transfer
of sole responsibility for diabetes
management to the developing child/
teenager. (B)
c Directly ask about diabetes-related
family conflict and stress and negoti-
ate an acceptable resolution with the
child/adolescent and parent(s). How-
ever, if family conflict is extremely en-
trenched and cannotbe resolved by the
diabetes team, referral should bemade
to a mental health specialist who is
knowledgeable about type 1 diabetes
in youth and family functioning. (C)
Additional Considerations for Adults
c Ongoing evaluation of patients’ gen-
eral and diabetes-related quality of
life, emotional well-being, distress,
depression, and resources is war-
ranted, preferably by a team that
includes a mental health specialist if
such resources are available. (C)
c Health care providers should promptly
address issues related to self-care ca-
pacity, mobility, and autonomy. (E)
NUTRITION THERAPY
Nutrition therapy is an important com-
ponent of the treatment plan for all in-
dividuals with type 1 diabetes. Each
patient should have an individualized
food plan based on food preferences,
schedule, and physical activity. Nutrition
therapy aims to ensure that the patient
and family understand the impact food
has on blood glucose, how food interacts
with exercise and insulin to prevent hypo-
and hyperglycemia and to achieve glu-
cose goals, and how to implement the
food plan in a variety of situations. The
food plan takes into consideration the pa-
tient’s numeracy, literacy, engagement,
and ability to adjust insulin.
General diabetes nutrition principles,
as defined in the ADA Standards of Care,
apply to people with type 1 diabetes,
particularly in reference to normal
growth and development in youth and
the maintenance of a healthy body
weight at all ages. Specifically, with re-
gards to individuals with type 1 diabetes,
topics such as carbohydrate counting and
meal composition should be addressed.
For selected individuals who have mas-
tered carbohydrate counting, education
on the impact of protein and fat on gly-
cemic excursions should be incorporated
into diabetes management (32). Those
who are overweight or obesemay benefit
from weight reduction counseling.
Recommendations
c Individualizedmedical nutrition therapy
is recommended for all people with
type 1 diabetes as an effective compo-
nent of the overall treatment plan. (A)
c Monitoring carbohydrate intake,
whether by carbohydrate counting
or experience-based estimation,
remains a key strategy in achieving
glycemic control. (B)
c If adults with type 1 diabetes choose
to drink alcohol, they should be ad-
vised to do so in moderation (one
drink per day or less for adult women
and two drinks per day or less for
adult men). Discussion with a health
care provider is advised to explore po-
tential interactions with medications.
Adults should be advised that alcohol
can lower blood glucose levels and that
driving after drinking alcohol is contra-
indicated. (E)
PHYSICAL ACTIVITY AND EXERCISE
Exercise has many positive health
and psychological benefits including
physical fitness, weight management,
and enhanced insulin sensitivity. It also
provides opportunities for social inter-
actions and builds self-esteem. How-
ever, exercise creates challenges for
people with type 1 diabetes due to the
increased risk for both hypoglycemia
and hyperglycemia. During exercise,
multiple hormones (insulin, glucagon,
catecholamines, growth hormone, and
cortisol) control fuel metabolism and
create a balance between glucose up-
take by exercising muscles and hepatic
glucose production (33,34). The equilib-
rium between insulin secretion and the
counterregulatory hormones varies ac-
cording to the exercise type, intensity,
and duration (35).
Hyperglycemia results from counter-
regulatory hormone excess with insuffi-
cient insulin, leading to excessive
hepatic glucose production and limiting
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increased glucose uptake into skeletal
muscle. Hyperglycemia can occur be-
fore, during, and after various types of
exercise. If the patient feels well, with
negative or minimal urine and/or blood
ketones, and there is a clear reason for
the elevated blood glucose level, such as
underdosing insulin at the preceding
meal, it is not necessary to postpone
exercise based solely on hyperglycemia.
However, when people with type 1 diabe-
tes are deprived of insulin for 12–48 h and
are ketotic, exercise can worsen hypergly-
cemia and ketosis. Therefore, vigorous
activity should be avoided in the presence
of severe hyperglycemia and ketosis, es-
pecially with known insulin omission.
Physical activity increases hypoglyce-
mia risk during and immediately follow-
ing exercise, and, again, about 7–11 h
postexercise. This delayed susceptibility
to hypoglycemia is referred to as the
“lag effect” of exercise (36,37) and is
caused by muscles replenishing glyco-
gen stores postexercise. Hypoglycemia
and fear of hypoglycemia can limit par-
ticipation in exercise.
Strategies should be developed to
prevent and treat hypoglycemia readily.
Individualization is necessary, but clini-
cal experience suggests that it is safest
for most patients to have a blood glu-
cose level of 100 mg/dL (5.6 mmol/L) or
higher prior to starting exercise. This
may be achieved by reducing the pran-
dial insulin dose for the meal/snack
preceding exercise and/or increasing
food intake. Some patients can avoid
hypoglycemia by reducing insulin
(such as by lowering pump basal rates)
(38) or by consuming additional carbo-
hydrates during prolonged physical
activity. One study in children on
pumps suggested that a reduction in
overnight basal insulin the night follow-
ing exercisemay reduce the risk of delayed
exercise-induced hypoglycemia (39). Fre-
quent SMBG and/or CGM use are key to
exercising safely, as is ready access to car-
bohydrates.
Basic recommendations for physical
activity are the same as those for all
children and adults, independent of
the diagnosis of diabetes: children
should be encouraged to engage in at
least 60 min of physical activity daily,
and adults should be advised to perform
at least 150 min/week of moderate-
intensity aerobic physical activity (50–
70% of maximum heart rate) or a lesser
amount (60–75 min/week) of vigorous-
intensity activity (40,41). Exercise
should also include resistance and flexi-
bility training.
Individuals, particularly adults, should
be assessed for cardiovascular risk and
the presence of complications that
might limit exercise as discussed more
fully in the ADA Standards of Medical
Care in Diabetes (42).
Recommendations
c Exercise should be a standard recom-
mendationas it is for individualswithout
diabetes; however, recommendations
may need modifications due to the
presence of macro- and microvascular
diabetes complications. (E)
c Patients of all ages (or caregivers of
children) should be educated about
the prevention and management of
hypoglycemia that may occur during
or after exercise. (E)
c Patients should be advised about safe
preexercise blood glucose levels (typ-
ically 100 mg/dL or higher depending
on the individual and type of physical
activity). (E)
c Reducing the prandial insulin dose for
the meal/snack preceding exercise
and/or increasing food intake can be
used to help raise the preexercise
blood glucose level and reduce hypo-
glycemia. (E)
c A reduction in overnight basal insulin
the night following exercise may re-
duce the risk for delayed exercise-
induced hypoglycemia. (C)
c SMBG should be performed as fre-
quently as needed (before, during,
and after exercise) in order to pre-
vent, detect, and treat hypoglycemia
and hyperglycemia. (E)
c Source(s) of simple carbohydrate
should be readily available before,
during, and after exercise to prevent
and treat hypoglycemia. (E)
TREATMENT TARGETS
General Considerations
Hyperglycemia defines diabetes and is
directly related to the incidence of com-
plications. Therefore, glycemic control is
fundamental to diabetes management.
The Diabetes Control and Complications
Trial (DCCT) (43) was a prospective ran-
domized controlled study comparing
intensive versus standard glycemic con-
trol in patients diagnosed with type 1
diabetes relatively recently. The DCCT
demonstrated that achieving an A1C of
,7% reduced the incidence of microvascu-
lar complications of type 1 diabetes com-
pared with standard control, which
achieved an A1C of ;9% during the pe-
riod of the randomized trial. The Epide-
miology of Diabetes Interventions and
Complications (EDIC) study (44,45)
was a follow-up of the DCCT cohorts.
The EDIC study remarkably demon-
strated persistentmicrovascular and car-
diovascular benefits in subjects who had
previously received intensive treatment,
even though their glycemic control had
deteriorated over time.
While A1C and blood glucose targets
are needed, the ADA emphasizes that
glycemic targets should be individual-
ized with the goal of achieving the best
possible control while minimizing the
risk of severe hyperglycemia and hypo-
glycemia (Table 7). Goals should be in-
dividualized based on duration of
diabetes, age/life expectancy, comorbid
conditions, known CVD or advanced
microvascular complications, hypogly-
cemia unawareness, and individual pa-
tient considerations. More or less
stringent glycemic goals may be appro-
priate for individual patients. Postpran-
dial glucose may be targeted if A1C goals
are notmet despite reaching preprandial
glucose goals.
Recommendation
c Lifestyle, psychosocial, and medical
circumstances should be considered
when recommending glycemic goals
for all age-groups. (E)
Glycemic Control Goals in Pediatrics
As the DCCT only included pediatric pa-
tients aged $13 years (195 adolescents
aged 13–17 years at entry), treatment
guidelines for pediatric patients have
been based nearly exclusively on profes-
sional, expert advice. Furthermore,
Table 7—Summary of A1C
recommendations for nonpregnant
people with diabetes*





Very complex/poor health ,8.5%
*Targets must be individualized based on
a patient’s circumstances. †No comorbidities,
long life expectancy.
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despite the overall A1C goal of,7% for
adults with type 1 diabetes, pediatric
patients, aged 13–19 years, had an A1C
target of ,7.5%. This slightly higher
A1C target for adolescents with type 1
diabetes was based on expert recom-
mendations and the clinical reality
that optimizing glycemic control in ado-
lescent patients with type 1 diabetes is
especially challenging, given the physio-
logical and behavioral challenges that
confront this age-group.
The ADA’s blood glucose and A1C
goals traditionally have been develop-
mentally or age based in the pediatric
population, but it is now time to alter
the traditional goals based on recent
data. The traditional recommendations
are an A1C goal of ,8.5% for youth un-
der the age of 6 years, ,8% for those
6–12 years old, and ,7.5% for those
13–19 years old. Lower blood glucose
levels and lower A1C targets should
be pursued as long as patients can avoid
severe, recurrent hypoglycemia. Thus,
the overall recommendation has in-
cluded the goal to achieve as close to
normal blood glucose and A1C levels as
is possible without the occurrence of
severe, recurrent hypoglycemia.
Historically, the ADA recommended
higher A1C targets for young children.
This recommendation arose from a
combination of two lines of unsubstan-
tiated evidence. First, an older body of
literature, reflecting therapy in the pre-
modern era, devoid of insulin analogs,
easy-to-use blood glucose monitors,
“smart pumps,” and CGM devices, indi-
cated that severe recurrent hypoglycemia
with seizure and/or coma in young chil-
dren was associated with neurocognitive
compromise (46). The second line of evi-
dence arose from literature that ques-
tioned what, if any, impact blood
glucose and A1C levels prior to puberty
have on the risk for the development of
future long-term complications of diabe-
tes (47,48).With the combination of these
two independent lines of reports, it is not
surprising that earlier recommendations
regarding glycemic targets focused on
the avoidance of severe hypoglycemia in
order to reduce risk of neurocognitive
dysfunction, especially in young children
and even school-aged children.
Currently, treatment strategies for
children recommend physiological insulin
replacement with modern strategies and
treatment tools.More recent investigation
andactiveongoing researchhavedispelled
concerns regarding hypoglycemia and
neurocognitive dysfunction (49,50).
Studies assessing neurocognitive
function have failed to identify adverse
effects of a past history of hypoglycemia
in the young child; however, as always,
further research needs to be conducted.
There are also questions regarding
the premise that the years prior to pu-
berty do not impact the future risk of
complications (51). Many investigators
and clinicians believe in the importance
of controlling blood glucose and A1C
levels prior to puberty to reduce risk
for both micro- and macrovascular
complications. Additionally, there is
burgeoning evidence that elevated
blood glucose levels and glycemic vari-
ability in the very young child with di-
abetes may produce adverse outcomes
in the short term on neurocognitive
function and the central nervous system
(52,53). These recent articles suggest that
hyperglycemia and glycemic variability
are associated with changes in the cen-
tral nervous system white matter, as
observed in MRI scans.
Taking into account the combination
of spotty past evidence related to the
adverse effects of hypoglycemia on the
developing brain and increasing evi-
dence from more recent investigations
focused on the potential risks of hyper-
glycemia and glucose variability on the
central nervous system, the ADA has de-
cided to alter the recommendations for
glycemic targets in pediatric patients
with type 1 diabetes and harmonizewith
other organizations. The International
Society for Pediatric and Adolescent Di-
abetes (ISPAD) uses a single A1C goal of
,7.5% across all pediatric age-groups.
This recommendation is based on clini-
cal studies and expert opinion, as rigor-
ous evidence does not currently exist.
Specifically, the recommendation is de-
rived from a combination of clinical ex-
perience and intensive management
strategies that provide opportunities
to achieve as near-normal glycemic con-
trol as possible without the occurrence
of severe hypoglycemia.
In light of the above evidence, the
ADA will harmonize its glycemic goals
with those of ISPAD (as well as the Pe-
diatric Endocrine Society and the Inter-
national Diabetes Federation) by using a
single A1C goal of <7.5% across all pedi-
atric age-groups.
However, as mentioned previously, it
must be emphasized that the ADA
strongly believes that blood glucose
and A1C targets should be individualized
with the goal of achieving the best pos-
sible control while minimizing the risk of
severe hyperglycemia and hypoglycemia
and maintaining normal growth and
development.
Recommendation
c AnA1C goal of,7.5% is recommended
across all pediatric age-groups. (E)
Glycemic Control Goals in Adults
Similar to in children, the care of older
adults with diabetes is complicated
by their clinical and functional hetero-
geneity. Unlike the large older adult pop-
ulation with type 2 diabetes, which
includes patients with both long-standing
and new-onset diabetes, most older
adults with type 1 diabetes have long-
standing disease. Even so, there is a
wide spectrum of health across older
individuals. They may have advanced
complications, or they may have lived
with diabetes for many years without
the development of complications.
Some older patients have multiple co-
morbid conditions and/or impairments
of physical or cognitive functioning,
while others have little comorbidity
and high functional status. Life expec-
tancy is highly variable and is defined
by comorbidity and functional status
more than it is by age.
Health care providers caring for older
adults with diabetes must take this het-
erogeneity into consideration when set-
ting and prioritizing treatment goals.
The benefits of interventions such as
stringent glycemic control may not ap-
ply to those with advanced complica-
tions of diabetes or to those with a life
expectancy of less than the anticipated
time frame of benefit. Conversely, the
risks of interventions such as tight gly-
cemic control (hypoglycemia, treatment
burden) may be greater in older pa-
tients. Although individualization is crit-
ical, in general, older patients with long
life expectancy and little comorbidity
should have treatment targets similar
to those of middle-aged or younger
adults. In more frail patients, treatment
targets might reasonably be relaxed,
while symptomatic hyperglycemia or
the risk of DKA should still be avoided
(54).
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Recommendations
c Lowering A1C to below or around 7%
has been shown to reduce microvas-
cular complications of diabetes, and,
if achieved soon after the diagnosis of
diabetes, is associatedwith long-term
reduction in macrovascular disease.
Therefore, a reasonable A1C goal for
many nonpregnant adults with type 1
diabetes is ,7%. (B)
c Providers might reasonably suggest
more stringent A1C goals (such as
,6.5%) for select individual pa-
tients, if this can be achieved with-
out significant hypoglycemia or
other adverse effects of treatment.
Appropriate patients might include
those with a short duration of
diabetes, a long life expectancy, hy-
poglycemia awareness, and no sig-
nificant CVD. (C)
c Less stringent A1C goals (such as
,8.5%) may be appropriate for pa-
tients with a history of severe hypogly-
cemia, hypoglycemia unawareness,
limited life expectancy, advanced
microvascular/macrovascular compli-
cations, or extensive comorbid condi-
tions. (B)
c Glycemic control for those of any age
with type 1 diabetes should be as-
sessed based on frequent SMBG lev-
els (and CGM data, if available) in
addition to A1C in order to direct
changes in therapy. (B)
MONITORING
SMBG
The DCCT demonstrated the benefits of
intensive glycemic control on diabetes
complications with SMBG as part of a
multifactorial intervention, suggesting
that SMBG is a crucial component of ef-
fective therapy. SMBG allows patients
to evaluate their individual response to
therapy and assess whether glycemic
targets are being achieved. SMBG results
are useful in preventinghypoglycemia, ad-
justing medications (particularly prandial
insulin doses), and understanding the im-
pact of appropriate nutrition therapy and
physical activity. More frequent SMBG is
correlated to lower A1C levels (55,56).
SMBG frequency and timing should
be dictated by the patient’s specific
needs and goals. When prescribing
SMBG, providers must ensure that pa-
tients receive ongoing instruction and
regular evaluation of their SMBG tech-
nique and their ability to use SMBG data
to adjust therapy (insulin and/or food).
Furthermore, SMBG results should be
downloaded and reviewed at each visit.
SMBG is especially important for pa-
tients with type 1 diabetes to monitor
for and prevent asymptomatic hypogly-
cemia and hyperglycemia. Type 1 dia-
betic patients should perform SMBG
prior to, and sometimes after, meals and
snacks, at bedtime, before and after exer-
cise,when they suspect lowbloodglucose,
after treating low blood glucose until they
are normoglycemic, and prior to critical
tasks such as driving. For many patients,
this will require testing 6–10 times daily,
although individual needs may vary. For
example, sick children may require up to
10 SMBG tests per day or more.
A study of children and adolescents
with type 1 diabetes showed that,
after adjustment for multiple con-
founders, increased SMBG frequency
was significantly associated with lower
A1C. In the range of 0–5 tests per
day, A1C decreased by 0.46% per addi-
tional test per day. Increased testing
was associated with significantly less
DKA and (probably due to reverse cau-
sality) significantly more hypoglycemia
(55,56).
SMBG accuracy is dependent on both
the instrument and the user (57), so it is
important to evaluate each patient’s
monitoring technique, both initially
and at regular intervals thereafter. Op-
timal use of SMBG requires a proper re-
view and interpretation of the data by
both the patient and the provider.
CGM
Real-time CGM through the measure-
ment of interstitial glucose (which cor-
relates well with plasma glucose) is
available. These sensors require calibra-
tion with SMBG, and CGM users still re-
quire SMBG for making acute treatment
decisions. CGM devices have alarms for
hypo- and hyperglycemic excursions
that include absolute level and rate-of-
change alerts. A 26-week randomized
trial of 322 type 1 diabetic patients
showed that adults aged $25 years us-
ing intensive insulin therapy and CGM
experienced a 0.5% reduction in A1C
(from ;7.6% to 7.1%) compared with
usual intensive insulin therapy with
SMBG (58). Participants aged,25 years
(children, teenagers, and young adults)
randomized to sensor use did not
achieve a significant A1C reduction.
However, these younger patients did
not use CGM consistently. The greatest
predictor of A1C lowering for all age-
groups was frequency of sensor use,
which was lowest in 15- to 24-year-old
subjects. There was no significant differ-
ence in hypoglycemia in any age-group.
In a smaller randomized controlled trial
of 129 adults and children with baseline
A1C ,7.0%, outcomes combining A1C
and hypoglycemia favored the group us-
ing CGM, suggesting that CGM is benefi-
cial for pediatric patients and adults
with type 1 diabetes who have already
achieved excellent control (58).
Overall, meta-analyses suggest that,
compared with SMBG, CGM use is asso-
ciated with A1C lowering by ;0.26%
(59) without an increase in hypoglyce-
mia, although existing studies have
small sample sizes and are of relatively
short duration. The technology may be
particularly useful in those with hypo-
glycemia unawareness and/or frequent
hypoglycemic episodes, although stud-
ies have not consistently shown signifi-
cant reductions in the occurrence of
severe hypoglycemia. A CGM device
equipped with an automatic low thresh-
old suspend feature was approved by the
U.S. Food and Drug Administration (FDA)
in 2013. The Automation to Simulate
Pancreatic Insulin Response (ASPIRE) trial
of 247 patients showed that sensor-
augmented insulin pump therapy with a
low glucose suspend feature significantly
reduced nocturnal hypoglycemia without
increasing A1C levels for those.16 years
of age (60). These devices may offer the
opportunity to reduce severe hypoglyce-
mia for those with a history of nocturnal
hypoglycemia, although more clinical tri-
als are needed.
Recommendations
c Patients with type 1 diabetes should
perform SMBG prior to meals and
snacks, at a minimum, and at other
times, including postprandially to assess
insulin-to-carbohydrate ratios; at bed-
time; midsleep; prior to, during, and/or
after exercise; when they suspect low
blood glucose; after treating low blood
glucose until they have restored normo-
glycemia; when correcting a high blood
glucose level; prior to critical tasks such
as driving; and at more frequent inter-
vals during illness or stress. (B)
c Individuals with type 1 diabetes need
to have unimpeded access to glucose
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test strips for blood glucose testing.
Regardless of age, individuals may re-
quire 10 or more strips daily to mon-
itor for hypoglycemia, assess insulin
needs prior to eating, and determine
if their blood glucose level is safe
enough for overnight sleeping. (B)
c CGM is a useful tool to reduce A1C
levels in adults without increasing hy-
poglycemia and can reduce glycemic
excursions in children. Glycemic im-
provements are correlated with fre-
quency of CGMuse across all ages. (A)
Additional Considerations for
Pediatrics
c Children should have additional
blood glucose checks if the parent/
caregiver is concerned that the child’s
behavior may be due to low/high
blood glucose levels. (E)
c School employees and caregivers
should be knowledgeable about
SMBG and equipped with all neces-
sary supplies. (E)
c Capable children should be permitted to
self-manage their diabetes at school. (E)
A1C TESTING
A1C reflects average glycemia over 2–3
months (57) and strongly predicts dia-
betes complications (43,61). Thus, A1C
testing should be performed routinely in
all patients with diabetes at initial as-
sessment and as part of continuing
care. A1C is a convenient method to
track diabetes control; however, there
are disadvantages. Glycation rates, and
thus A1C levels, may vary with patients’
race/ethnicity. However, this is contro-
versial. Additionally, anemias, hemoglo-
binopathies, and situations of abnormal
red cell turnover affect A1C (42).
A1C measurements approximately
every 3 months determine whether a
patient’s glycemic targets have been
reached and maintained. For any indi-
vidual patient, the frequency of A1C
testing should be dependent on the clin-
ical situation, the treatment regimen
used, and the clinician’s judgment. Un-
stable or highly intensively managed pa-
tients (e.g., pregnant type 1 diabetic
women) may require more frequent
testing than every 3 months (62). In pa-
tients with hemoglobinopathies that in-
terfere with the A1C assay or with
hemolytic anemia or other conditions
that shorten the red blood cell life
span, the A1C may not accurately reflect
glycemic control or correlate well with
SMBG testing results. In such conditions,
fructosaminemay be considered as a sub-
stitute measure of long-term (average
over 2 weeks) glycemic control.
Recommendations
c Perform the A1C test quarterly in
most patients with type 1 diabetes
and more frequently as clinically in-
dicated (i.e., pregnancy). (A)
c Point-of-care A1C testing, using a
DCCT standardized assay, may pro-
vide an opportunity for more timely
treatment changes. (E)
INSULIN THERAPY
The DCCT clearly showed that intensive
insulin therapy, defined as three or
more injections per day of insulin or con-
tinuous subcutaneous insulin infusion
(CSII) (or insulin pump therapy), was a
key part of improved glycemia and better
outcomes (43,63). The study was carried
out with short- and intermediate-acting
human insulins. Despite bettermicrovas-
cular outcomes, intensive insulin ther-
apy was associated with a high rate of
severe hypoglycemia (62 episodes per
100 patient-years of therapy). Since the
completion of the DCCT, a number of
rapid-acting and long-acting insulin
analogs have been developed. These
analogs are associated with less hypogly-
cemia than human insulin while offering
the same amount of A1C lowering in
people with type 1 diabetes (64,65).
The Sensor-Augmented Pump Ther-
apy for A1C Reduction (STAR 3) study
was a large (n 5 485) randomized clini-
cal trial comparing insulin pump therapy
and CGMwith insulin injections in youth
and adults with type 1 diabetes. The two
study groups started with the same
baseline A1C of 8.3%. After 1 year, the
group using insulin pump therapy and
CGM had lower A1C levels (7.5% vs.
8.1%, P , 0.001) without significant
nocturnal hypoglycemia compared
with the insulin injection cohort (66).
Recently, a large randomized trial in pa-
tients with type 1 diabetes and noctur-
nal hypoglycemia reported that the
use of sensor-augmented insulin pump
therapy with the threshold-suspend fea-
ture reduced nocturnal hypoglycemia
without increasing glycated hemoglobin
values (60). In general, intensive man-
agement using pump therapy/CGM
should be strongly encouraged, with
active patient/family participation en-
hancing successful outcomes (67–69).
Recommendations
c Most individuals with type 1 diabetes
should be treated with multiple daily
insulin injections (three or more in-
jections per day of prandial insulin
and one to two injections of basal in-
sulin) or CSII. (A)
c Most individuals with type 1 diabetes
should be educated in how to match
prandial insulin dose to carbohydrate
intake, premeal blood glucose, and
anticipated activity. (E)
c Most individuals with type 1 diabetes
should use insulin analogs to reduce
hypoglycemia risk. (A)
c All individuals with type 1 diabetes
should be taught how tomanage blood
glucose levels under varying circum-
stances, such as when ill or receiving
glucocorticoids or for those on pumps,
when pump problems arise. (E)
c Child caregivers and school personnel
should be taught how to administer
insulin based on provider orders
when a child cannot self-manage
and is out of the care and control of
his or her parent/guardian. (E)
INTERDICTION
Therapy trials to prevent type 1 diabetes
development (prevention), to preserve
remaining b-cells (preservation), and to
replace b-cells (transplantation) are on-
going. Although means are available to
screen and predict family members at
risk for developing type 1 diabetes, ef-
forts to delay or prevent disease onset
have been largely disappointing. A vari-
ety of different immunomodulatory and
immune-suppressive agents have been
evaluated in patients with recent-onset
type 1 diabetes, and the effects have
been modest at best: for the subset of
drugs that appear to have an effect, not
all patients respond; for those who do,
the effects are generally transient.
Many of the agents tested to date are
FDA approved for other indications, but
given the observations to date and po-
tential toxicities, the recommendation is
that patients should only receive these
drugs after being enrolled in clinical
research protocols with appropriate
follow-up. Long-term safety and efficacy
data are scarce, especially in children. In-
vestigators continue to evaluate prom-
ising new agents and combinations of
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drugs or cell-based therapies in an effort
to safely and effectively modulate the
autoimmune response (70).
b-CELL REPLACEMENT THERAPY
b-Cell replacement may be achieved
through pancreas or islet transplantation
in select candidates. Pancreas transplants
are now accepted as a proven therapy,
while islet transplants, though signifi-
cantly improving, are still mostly done
on an experimental basis.
Pancreas Transplants
Pancreas transplants are most often
performed in combination with kidney
transplantation, either as a simulta-
neous pancreas-kidney (SPK) transplant
or as a pancreas-after-kidney (PAK)
transplant (71). SPK and PAK transplants
may be considered for individuals
with late-stage kidney disease because
the transplants can normalize glucose
levels, which will prevent hypogly-
cemia and provide some protection for
the transplanted kidney (72), and provide
other benefits, including an improvement
in quality of life (71). These recipients will
already require immunosuppression for
their renal transplants, which means the
major additional risk is the operative pro-
cedure. SPK transplants function for an
average of 9 years, comparedwith 6 years
for PAK transplants (71).
There has been debate about pan-
creas transplant alone (PTA) in the ab-
sence of an indication for kidney
transplantation because of the risks of
mortality, morbidity, and immunosup-
pression. Outcomes have gradually im-
proved (73), such that the procedure
can be cautiously considered for indi-
viduals without renal failure who have
unstable glucose control and hypogly-
cemia unawareness. Because of the
risks of pancreas transplantation com-
pared with traditional methods for
controlling blood glucose levels, all
available efforts to use exogenous insu-
lin combined with technology, educa-
tion, and glucose follow-up should be
exhausted before PTA is performed.
The durability of function averages 6
years, which is much better than islet
transplantation but about the same as
PAK and not as good as SPK (73).
Islet Transplantation
Amajor appeal of islet transplantation is
that it does not require major surgery.
Moreover, outcomes have improved
over the past decade such that normo-
glycemia without insulin is now main-
tained for an average of 3 years in
specialized protocols (74). Even when
insulin treatment is reinstituted, resid-
ual insulin secretion can help recipients
maintain good control with less hypo-
glycemia and a less complicated regi-
men for several more years.
At the present time, few islet trans-
plants are being performed and most
are experimental. However, they can
be considered as a treatment option
for those who are poor candidates for
whole-organ transplants. Importantly,
their current success has established a
proof of principle for cellular transplanta-
tion. Great progress is being made in
finding an abundant source of healthy
insulin-producing cells and in developing
better ways to protect transplanted cells
from immune destruction (75,76). Poten-
tial solutions for the shortage of islets in-
clude embryonic stem cells, induced
pluripotent stem cells, xenogeneic tissue,
and various other potential sourcesdall
the focus of ongoing research efforts. An-
other possible way to replenish the b-cell
deficiency of diabetes is through regener-
ation of the endocrine pancreas; this too
is being worked on intensively.
Recommendations
c Consider solid organ pancreas trans-
plantation simultaneously with kidney
transplantation in patients with type 1
diabetes who have an indication for
kidney transplantation and are poorly
controlled with large glycemic excur-
sions. (B)
c Consider solid organ pancreas trans-
plantation after kidney transplanta-
tion in adult patients with type 1
diabetes who have already received a
kidney transplant. (C)
c Judiciously consider solid organ pan-
creas transplantation alone in adults
with type 1 diabetes, unstable glucose
control, hypoglycemia unawareness,
and an increased risk of diabetes-
relatedmortality, whohave attempted
all of the more traditional approaches
to glycemic control and have re-
mained unsuccessful, yet are judged
responsible enough tomanage the an-
tirejection medication regimen, risks,
and follow-up required with an organ
transplant. (C)
c Consider referral to research centers for
protocolized islet cell transplantation
in patients with type 1 diabetes and
debilitating complications of diabetes
who are interested in research possi-




Pramlintide, an amylin analog, is an
agent that delays gastric emptying,
blunts pancreatic secretion of glucagon,
and enhances satiety. It is an FDA-
approved therapy for use in type 1 di-
abetic patients and has been shown to
reduce A1C, induce weight loss, and
lower insulin dose. However, it is only
indicated for adults. Two 52-week trials
of pramlintide (n 5 1,131; age .18
years) showed A1C reductions of
;0.3–0.4% (77,78). In both studies, a
greater proportion of participants
achieved an A1C target of ,7% with
the therapy than without the therapy.
There are a few small, short-term stud-
ies of pramlintide use in children with
type 1 diabetes, with outcomes similar
to those in the adult studies. Clearly,
larger, long-term studies are needed
in pediatrics.
Incretin-Based Therapies
Injectable glucagon-like peptide-1 (GLP-1)
agonists and oral dipeptidyl peptidase-4
(DPP-4) inhibitors are increasingly being
studied in the type 1 diabetic population,
but are not approved by the FDA for
this indication. GLP-1 agonists delay
gastric emptying, suppress the postpran-
dial rise in glucagon secretion, and may
increase satiety. Preliminary studies in-
dicate that these agents may also facili-
tate weight loss. Further long-term




Sodium-glucose cotransporter 2 (SGLT2)
inhibitors work by inhibiting glucose re-
absorption in the kidney and are also
being tested in individuals with type 1
diabetes. These agents provide insulin-
independent glucose lowering by
blocking glucose reabsorption in the
proximal renal tubule, leading to weight
loss and A1C reduction in individuals
with type 2 diabetes. However, insuffi-
cient data exist to recommend clinical
use of these agents in type 1 diabetes at
this time.
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Metformin
Metformin is a biguanide that decreases
hepatic gluconeogenesis and is used as
first-line therapy in type 2 diabetes. It
has been shown to have some benefit
in reducing insulin doses and weight in
small studies in patients with type 1 di-
abetes (79) and is now being evaluated
more fully for use in patients with type 1
diabetes. Two randomized controlled
trials are currently under way evaluating
metformin in type 1 diabetic patients. The
first study is in adults and is using carotid
intima-medial thickness as an outcome
measure (ClinicalTrials.gov identifier:
NCT01483560). The second study is focus-
ing on overweight or obese youths be-
tween the ages of 12 and 19 years who
require$0.85units/kg/dayof insulin (Clin-
icalTrials.gov identifier: NCT01808690).
Results are currently pending.
Recommendations
c Pramlintide may be considered for
use as adjunctive therapy to pran-
dial insulin in adults with type 1 di-
abetes failing to achieve glycemic
goals. (B)
c Evidence suggests that adding met-
formin to insulin therapy may reduce
insulin requirements and improve
metabolic control in overweight/
obese patients and poorly controlled
adolescents with type 1 diabetes, but
evidence from larger longitudinal
studies is required. (C)
c Current type 2 diabetes medications
(GLP-1 agonists, DPP-4 inhibitors, and
SGLT2 inhibitors) may be potential
therapies for type 1 diabetic patients,
but require large clinical trials before
use in type 1 diabetic patients. (E)
HYPOGLYCEMIA
Hypoglycemia risk is the limiting step in
the treatment of type 1 diabetes at any
age. Because current methods of blood
glucose detection and insulin replace-
ment are imperfect (though improved
from prior eras), hypoglycemia risk is
invariably present. Patient education
(80), frequent SMBG, and CGM can
help detect hypoglycemia and allow
for adjustments in insulin dosing and
carbohydrate intake. Severe hypoglycemia
rates increase with antecedent episodes
of hypoglycemia, age, and duration of
diabetes; thus, this is an issue that
must be reassessed frequently (81). Hy-
poglycemia unawareness is related to a
reduced sympathoadrenal response to
hypoglycemia; it can occur in the setting
of recurrent hypoglycemia or autonomic
failure and can be reversed by scru-
pulous avoidance of hypoglycemia. Pa-
tients should be screened to determine
the threshold at which hypoglycemia
symptoms occur; if the threshold is sug-
gestive of hypoglycemia unawareness,
the treatment goals and regimen should
be revisited and counseling regarding ap-
propriate self-monitoring before critical
tasks should be reinforced (82).
Oral carbohydrate is the treatment of
choice for self-treatment or for the
treatment of hypoglycemic adults and
children who are alert and able to eat.
Glucagon is used for severe hypoglyce-
mia. In children, small studies have led
to the concept of using age-based mini-
dose glucagon if the child is alert but not
able to eat (83).
Recommendations
c Individualswith type1diabetes, or their
caregivers, should be asked about
symptomatic and asymptomatic hypo-
glycemia at each encounter. (E)
c Glucose (15–20 g) is the preferred
treatment for the conscious individ-
ual with hypoglycemia, although any
form of carbohydrate may be used.
If the SMBG result 15 min after treat-
ment shows continued hypoglycemia,
the treatment should be repeated.
Once blood glucose concentration re-
turns to normal, the individual should
consume a meal or snack to prevent
recurrence of hypoglycemia. (E)
c Glucagon should be prescribed for all
individuals with type 1 diabetes.
Caregivers or family members of
these individuals should be instructed
in its administration. (E)
c Hypoglycemia unawareness or one or
more episodes of severe hypoglyce-
mia should trigger reevaluation of
the treatment regimen. (E)
c Insulin-treated patients with hypogly-
cemia unawareness or an episode
of severe hypoglycemia should be ad-
vised to raise their glycemic targets to
strictly avoid further hypoglycemia for
at least several weeks to partially re-
verse hypoglycemia unawareness and
reduce the risk of future episodes. (B)
DKA
DKA (see ref. 70 for definition) is an acute
complication of diabetes that can be
associated with new-onset type 1 diabe-
tes, insulin omission, and increased levels
of counterregulatory hormones/cytokines
associatedwith stress, suchasan infection.
Mild cases can be safely and effectively
treated in an acute care setting with ap-
propriate resources and may not require
hospitalization. Education must be pro-
vided to individuals with type 1 diabetes
in order to help prevent DKA, which can
have serious sequelae, particularly in chil-
dren under 5 years of age. Although DKA
and hyperglycemic hyperosmolar state
(HHS) may overlap, especially when dehy-
dration is severe, DKA must be distin-
guished from HHS (serum glucose .600
mg/dL, serumosmolality.330mOsm/kg,
and no significant ketosis and acidosis)
because patients with HHS typically are
severely dehydrated and require more
aggressive fluid management. There are
multiple guidelines available for the
management of DKA (84).
Recommendations
c Individuals and caregivers of individ-
uals with type 1 diabetes should be
educated and reminded annually
how to prevent DKA, including a re-
view of sick-day rules and the critical
importance of always administering
insulin and monitoring both glucose
and ketone levels. (B)
c Insulin omission is the major cause of
DKA; therefore, individuals with type
1 diabetes must have access to an un-
interrupted supply of insulin. (E)
c Patients with type 1 diabetes and their
families should have around-the-clock
access tomedical advice and support to
assist with sick-day management. (C)
c Standard protocols for DKA treat-
ment should be available in emer-
gency departments and hospitals. (E)
CVD SCREENING AND TREATMENT
Much of the existing data on the risk of
CVD in individuals with diabetes is based
on people with type 2 diabeteswho often
have additional CVD risk factors, such as
metabolic syndrome, hypertension, and
dyslipidemia. How much is applicable to
people with type 1 diabetes is unknown.
However, people with type 1 diabetes are
at increased risk for CVD, particularly
those with additional risk factors.
In type 1 diabetes, standard risk factors
apply, such as hyperlipidemia, hyperten-
sion, age, family history, smoking, weight,
and presence of albuminuria. As such,
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these should be considered when deter-
mining the need for evaluation and treat-
ment for CVD. However, even in the
absence of classic risk factors, there may
behigh CVD risk. An adultwith childhood-
onset type 1 diabetes of 20-year duration
has a substantially increased risk of coro-
nary artery disease of 1% per year (83),
thus meriting high-intensity statin ther-
apy according to the new joint American
College of Cardiology/American Heart As-
sociation guidelines ($7.5% 10-year risk)
(85). In some cases, measurement of cor-
onary artery calcification may be a help-
ful method for determining CVD risk
(86). Here, as with all management is-
sues for people with type 1 diabetes,
providers need to individualize assess-
ment and treatment options.
With regard to treatment, statin ther-
apy is the preferred treatment for lipid
lowering/CVD risk reduction (85). The
Heart Protection Study (HPS) did include
type 1 diabetic participants who ap-
peared to experience the same degree
of benefit from statins as others in the
study, though the finding was not statis-
tically significant due to low numbers
(87). Unfortunately, there are no blood
pressure intervention trials with CVD
end points in type 1 diabetes and only
one LDL cholesterol–lowering trial (85).
Statin and aspirin therapy (if not contra-
indicated) should be considered and used
as is individually indicated.
Recommendations
c Therapy for those under age 40 years
with less than a 20-year diabetes dura-
tion (or over age 75 years) should be
considered on an individual basis,
though, depending on overall risk, an
LDL cholesterol ,100 mg/dL has been
suggested as an appropriate goal with
statin intervention for those with LDL
cholesterol levels of 130–160mg/dL. (E)
c Individualswith type1diabetesaged40–
75 years may benefit from moderate-
to-intensive statin therapy with consid-
eration of diabetes duration and CVD
risk factors. If 10-year risk is estimated
to be $7.5%, then intensive statin




Preconception Counseling and Care
To minimize risks associated with preg-
nancy and type 1 diabetes, preconception
counseling and care are critical. Precon-
ception care with tight glycemic control
improves outcomes including lower ce-
sarean rates (88), decreased perinatal
mortality (89–91), anddecreased congen-
ital malformations (89–97). Although
there is some evidence that childbearing
may be reduced (98–100), in general, fer-
tility should be assumed to be normal,
and all young women with type 1 diabe-
tes should receive preconception coun-
seling covering diabetes and general
topics, including use of prenatal vitamin,
discontinuation of potentially teratogenic
medications, and the importance of gly-
cemic control to reduce the risk of con-
genital malformations.
Pregnancy
Type 1 diabetes affects approximately
0.1–0.2% of all pregnancies (101). Dur-
ing pregnancy, there are substantial
changes in maternal insulin sensitivity
that may cause profound changes in in-
sulin requirements. Whereas insulin re-
sistance increases markedly during the
second and third trimesters, a greater
proportion of total daily insulin dose
must be given prandially and a lower
proportion used to cover basal meta-
bolic requirements (102). Pregnant
women with type 1 diabetes require
meticulous glycemic management by
experts trained in obstetrics, endocri-
nology, and maternal-fetal medicine.
Women who are planning pregnancy
or who are pregnant may need to test
blood glucose levels frequently (often
10 or more times daily) to reach and
maintain a near-normal A1C level with-
out excessive hypoglycemia.
Severe hypoglycemia may occur early
during pregnancy (102). This is followed
by periods of insulin resistance and sub-
sequent hyperglycemia if the increased
insulin needs are not met. Therefore,
health care providers must be vigilant
and frequently adjust insulin dosing
throughout gestation.
In a pregnancy complicated by dia-
betes and chronic hypertension, target
blood pressure goals of systolic blood
pressure 110–129 mmHg and diastolic
blood pressure 65–79 mmHg are reason-
able. Lower blood pressure levels may be
associated with impaired fetal growth
(Table 8). ACE inhibitors and angiotensin
receptor blockers are contraindicated
during pregnancy because they may
have adverse effects on the fetus. Antihy-
pertensive drugs known to be effective
and safe in pregnancy include methyl-
dopa, labetalol, diltiazem, clonidine, and
prazosin.
Eye examinations should occur in the
first trimester with close follow-up
throughout pregnancy and for 1 year
postpartum because of the risk of rapid
retinopathy progression during preg-
nancy. Those with progressive retino-
pathy should have more frequent
screening by an ophthalmologist expe-
rienced in retinopathy management.
See the American Diabetes Association/
JDRF Type 1 Diabetes Sourcebook (70)
for a summary of pregnancy recommen-
dations. The prevalence of Hashimoto
thyroiditis may be as high as 31% in
women with type 1 diabetes (105).
Therefore, all pregnant women with
type 1 diabetes should be screened for
thyroid disease early in pregnancy.
Recommendations
c Starting at puberty, preconception
counseling should be incorporated
into routine diabetes clinic visits for
all adolescents and women of child-
bearing potential, and appropriate
birth control techniques should be
discussed with women who do not
desire pregnancy. (C)
Table 8—ADA Standards of Care optimal targets in pregnancy*
Target maternal glucose†
Fasting 60–99 mg/dL
Peak postprandial 100–129 mg/dL
Mean ,100 mg/dL
Labor and delivery 80–110 mg/dL (mean ,100)
Insulin drips 1 D10 50 cc/h
A1C Preconception ,7% and as close to normal as possible
without significant hypoglycemia
During pregnancy ,6%
*See refs. 70, 103, and 104. †These represent the mean12 SD for normal. They are targets, but
not everyone can achieve them. There is certainlymarked variability, which explains why there is
greater incidence of large-for-gestational-age infants in patients with type 1 diabetes.
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c As most pregnancies are unplanned,
consider the potential risks and ben-
efits of medications that are contrain-
dicated in pregnancy in all adolescents
and women of childbearing potential
and counsel women using such medi-
cations accordingly. (E)
c Such medications should be evalu-
ated prior to conception, as drugs
commonly used to treat diabetes
and its complications may be con-
traindicated or not recommended
in pregnancy, including statins, ACE
inhibitors, angiotensin receptor
blockers, and most noninsulin ther-
apies. (B)
c Prenatal vitamins with folate should
be started with preconception plan-
ning to reduce the risk for birth de-
fects. (B)
c All pregnant women with type 1 di-
abetes should be screened for thyroid
disease early in pregnancy. (B)
c Women contemplating pregnancy
should be evaluated and, if indicated,
treated for diabetic retinopathy, ne-
phropathy, neuropathy, and CVD. (B)
c A1C levels should be as close to nor-
mal as possible (,7%) before concep-
tion is attempted. (B)
c Nutritional intake should be opti-
mized and included in preconception




Management of individuals with type 1
diabetes in the hospital and in prepara-
tion for scheduled outpatient pro-
cedures often differs from that of
individuals with type 2 diabetes. The
challenges include difficulties associ-
ated with fasting, maintaining a con-
sistent source of carbohydrate, and
facilitating inpatient blood glucoseman-
agement while modifying scheduled in-
sulin therapy. Outpatient procedures
should be performed with the aware-
ness that individuals with type 1 diabe-
tes may have difficulty fasting for long
periods of time (more than 10 h) prior to
a procedure. Patients with type 1 diabetes
should be prepared with a treatment plan
for insulin dose adjustments and oral glu-
cose intake prior to any procedure that
requires alterations in dietary intake and/
or fasting.
It is imperative that the entire health
care team, including anesthesiologists
and surgeons as well as other specialists
who perform procedures, understands
type 1 diabetes and how it factors into
the comprehensive delivery of care.
From a practical perspective, this means
that people with type 1 diabetes will
be at high risk for hypoglycemia during
prolonged fasting and are at risk for
ketosis if insulin is inappropriately with-
held. Once under anesthesia, individ-
uals with type 1 diabetes must be
carefully monitored for hypoglycemia
and hyperglycemia.
For some individuals, once the most
acute phase of an illness has resolved
or improved, patients may be able to
self-administer their prior multiple-
dose or CSII insulin regimen under the
guidance of hospital personnel who are
knowledgeable in glycemic manage-
ment. Individuals managed with insulin
pumps and/or multiple-dose regimens
with carbohydrate counting and cor-
rection dosing may be allowed to man-
age their own diabetes if this is what
they desire, once they are capable of
doing so.
Recommendations
c All patients admitted to the hospital
should have type 1 diabetes clearly
identified in the medical record. (E)
c SMBG should be ordered to fit the
patient’s usual insulin regimen with
modifications as needed based on
clinical status. (E)
c Goals for blood glucose levels are the
same as for people with type 2 diabe-
tes or hospital-related hyperglyce-
mia. (E)
c A plan for preventing and treating hy-
poglycemia should be established for
each patient. (E)
c Insulin dosing adjustments should be
made in the perioperative period and
inpatient setting with consideration
of changes in oral intake, recent
blood glucose trends, and the need
for uninterrupted basal insulin to pre-
vent hyperglycemia and ketoacidosis,
with adjustment of the long-acting in-
sulin or basal insulin requirement to
reflect true basal requirements, inso-
far as they may be anticipated. (B)
Child Care and Schools
Because a large portion of a child’s day
may be spent in school and/or in the
child care setting, close communication
with and cooperation of the school or day
care personnel is essential for optimal di-
abetesmanagement, safety, andmaximal
academic opportunities. Child care per-
sonnel and school staff should receive
training to provide diabetes care in the
absence of a school nurse or licensed
health care professional. Able and willing
school staff members should be taught
the principles of diabetes management
and trained to provide needed care for
the child according to the ADA’s Safe at
School program (see the ADA position
statement on diabetes care in the school
and day care setting [106] for further dis-
cussion). Young children often lack the
motor, cognitive, and communication
skills and abilities to manage their diabe-
tes and completely depend on adult care-
givers. The management priority for
younger children is the prevention, recog-
nition, and treatment of hypoglycemia
and marked hyperglycemia.
Students with diabetes should re-
ceive proper diabetes management
in school, with as little disruption to
the school and child’s routine as possi-
ble. Whenever possible, the student
should have the opportunity to self-
manage by performing blood glucose
monitoring, using CGM (if utilized), ad-
ministering insulin, having access to
meals/snacks, managing hypoglycemia
(with trained personnel prepared
to provide glucagon treatment, if re-
quired) and hyperglycemia, and partici-
pating fully in all school-sponsored
activities (Table 9).
Camps
A diabetes camp is an ideal place for
children and youth to have an enjoyable
camp experience and receive peer sup-
port from other children with diabetes
under close medical oversight. The
goals for campers are to learn to cope
more effectively with diabetes, learn
self-management skills to gain more in-
dependence, and share experiences
with other young people with diabetes.
The camp medical director is respon-
sible for the diabetes management of
the children. A registered dietitian over-
sees dietary planning at camp. Medical
directors and staff should have exper-
tise in managing type 1 diabetes and
must receive training concerning rou-
tine diabetes management and treat-
ment of diabetes-related emergencies
at camp. Staff must follow universal pre-
cautions including Occupational Safety
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and Health Administration (OSHA) regu-
lations, Clinical Laboratory Improve-
ment Amendments (CLIA) standards,
and state regulations (107).
Diabetes in the Workplace
There are practical and legal issues re-
lated to diabetes in the workplace. Em-
ployers and employees with diabetes
should work together to find solutions
and educate themselves about the
rights of individuals with diabetes. Indi-
viduals with diabetes are responsible for
having all necessary diabetes supplies,
eating properly, and being aware of
safety issues and regulations at work.
The Americans with Disabilities Act states
that most employers must provide “rea-
sonable accommodations” to allow an in-
dividual with diabetes to safely and
successfully perform a job, unless doing
sowould place an “undue burden” on the
employer. We refer the reader to ADA
position statement on diabetes and em-
ployment for additional information
(108) and to the relevant section of the
American Diabetes Association/JDRF
Type 1 Diabetes Sourcebook (70).
Older Adults
Older individuals with type 1 diabetes
are unique in that they have lived for
many years with a complex disease.
Not all older adults are alike: some
may continue a rigorous regimen, with
tighter control, while others may re-
quire less stringent targets. Along with
age-related conditions, older adults may
develop diabetes-related complications,
which make managing type 1 diabetes
more challenging. Providers should be
aware that insulin dosing errors, meal
planning, and physical activities must
be properly managed in older adults.
Severe hyperglycemia can lead to symp-
toms of dehydration and hyperglycemic
crises. While chronic hyperglycemia is
detrimental, hypoglycemia may be
more of a concern in some older adults.
Declining cognition may contribute to
hypoglycemia unawareness or the in-
ability to safely manage hypoglycemia
when it occurs. An individualized ap-
proach that includes the reassessment
of prior targets may be warranted. We re-
fer the reader to the ADA consensus report
“Diabetes in Older Adults” (54). Even
though this report focuses primarily on
the type 2 diabetic population, there is sig-
nificant overlap in the comorbidities and
complications experienced by the older
type 1 and type 2 diabetic populations.
Special Population Groups
Although type 1 diabetes is increasing in
several ethnic and racial groups, it
remains less common in people of non-
European descent. A better understand-
ing of the unique pathophysiology of
type 1 diabetes is needed. In addition,
multidisciplinary diabetes teams should
receive training to properly address the
diverse cultural needs of these popula-
tions and to optimize health care deliv-
ery, improve glycemic control, and
prevent complications. Additionally,
there is a need for approaches to reduce
health disparities and improve out-
comes in racial/ethnic minorities and
in the underserved population with
type 1 diabetes (70).
Developing Countries: The Global
Epidemic
Type 1 diabetes is an increasing global
public health burden. The demands of
daily management, chronicity of the dis-
ease, potential complications, paucity of
diabetes specialists, and rising incidence
are challenging in the U.S., but these
issues, including the considerable cost
of management, are crippling for those
in the developing world. International
organizations play a major role in im-
proving care for individuals with type 1
diabetes in the developing world, but
implementable, cost-saving, and sus-
tainable strategies are needed to make
such programs successful (70).
Table 9—Diabetes care tasks for school personnel







Glucose, wait 15 min, recheck,
give food if blood glucose is
adequate (based on DMMP)
Seizure or coma
Know when and how to give glucagon
Know when to contact parents or
emergency medical services




Polyuria, polydipsia (most common),
difficulty concentrating, headache,
or irritability
Rapid- or short-acting insulin Check for ketones. Follow
directions for ketones if
positive to avoid ketoacidosis
Dose and frequency should be
clearly elucidated on emergency






Ketone checks and when to
call parents
Correction factor calculations
and insulin for hyperglycemia
and ketones
DMMP, Diabetes Medical Management Plan. *Varies among individuals but consistent within a given child.
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